Levodopa-based device-aided therapies for the treatment of advanced Parkinson’s disease: a social return on investment analysis
Frontiers in Public Health · 06.06.2024 · 12
DOI: 10.3389/fpubh.2024.1351808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 06.06.2024. Verfasst von Inez Denham und 5 weiteren Autor:innen. Beteiligte Einrichtung: HTANALYSTS Pty Ltd., Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Parkinson Disease, Cost-Benefit Analysis, Levodopa. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Parkinson’s disease (PD) is an incurable, progressive, neurodegenerative disorder. As PD advances and symptoms progress, patients become increasingly dependent on family and carers. Traditional cost-effectiveness analyses (CEA) only consider patient and payer-related outcomes, failing to acknowledge impacts on families, carers, and broader society. This novel Social Return on Investment (SROI) analysis aimed to evaluate the broader impact created by improving access to levodopa (LD) device-aided therapies (DATs) for people living with advanced PD (aPD) in Australia.
Methods
A forecast SROI analysis over a three-year time horizon was conducted. People living with aPD and their families were recruited for qualitative interviews or a quantitative survey. Secondary research and clinical trial data was used to supplement the primary research. Outcomes were valued and assessed in a SROI value map in Microsoft Excel™. Financial proxies were assigned to each final outcome based on willingness-to-pay, economic valuation, and replacement value. Treatment cost inputs were sourced from Pharmaceutical Benefits Schedule (PBS) and Medicare Benefits Scheme (MBS) published prices.
Results
Twenty-four interviews were conducted, and 55 survey responses were received. For every $1 invested in access to LD-based DATs in Australia, an estimated $1.79 of social value is created. Over 3 years, it was estimated $277.16 million will be invested and $406.77 million of social return will be created. This value is shared between people living with aPD (27%), their partners (22%), children (36%), and the Australian Government (15%). Most of the value created is social and emotional in nature, including reduced worry, increased connection to family and friends, and increased hope for the future.
Discussion
Investment in LD-based DATs is expected to generate a positive social return. Over 50% of the value is created for the partners and children of people living with aPD. This value would not be captured in traditional CEA. The SROI methodology highlights the importance of investing in aPD treatment, capturing the social value created by improved access to LD-based DATs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HTANALYSTS Pty Ltd., Sydney, NSW, Australia.
- AbbVie Pty Ltd., Sydney, NSW, Australia.
- The George Institute for Global Health, Sydney, NSW, Australia.
Zitieren
APA
Denham, I., Maurin, R., Deltetto, I., Mikolaizak, A. S., Waern, J. B., & Taylor, C. (2024). Levodopa-based device-aided therapies for the treatment of advanced Parkinson’s disease: a social return on investment analysis. Frontiers in Public Health, 12. https://doi.org/10.3389/fpubh.2024.1351808
Vancouver
Denham I, Maurin R, Deltetto I, Mikolaizak AS, Waern JB, Taylor C. Levodopa-based device-aided therapies for the treatment of advanced Parkinson’s disease: a social return on investment analysis. Frontiers in Public Health. 2024;12. doi:10.3389/fpubh.2024.1351808
BibTeX
@article{Denham2024,
author = {Denham, Inez and Maurin, Roxanne and Deltetto, Irene and Mikolaizak, Anna Stefanie and Waern, Jenny B and Taylor, Colman},
title = {Levodopa-based device-aided therapies for the treatment of advanced Parkinson’s disease: a social return on investment analysis},
journal = {Frontiers in Public Health},
year = {2024},
volume = {12},
doi = {10.3389/fpubh.2024.1351808}
}
EUVIMED